Overview

Tolerability of SLIT With LAIS® Mites Allergoid Tablets

Status:
Completed
Trial end date:
2017-02-28
Target enrollment:
0
Participant gender:
All
Summary
To expand knowledge on the application and tolerability of immunotherapy with LAIS® Mites allergoid tablets as well as knowledge on the alleviation of symptoms during sublingual therapy in special consideration of the chosen titration schedule in everyday practice.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital of Cologne
Treatments:
Immunologic Factors
Criteria
Inclusion Criteria:

- Patients aged 18 years or older having allergies within the scope of specifications
stated in the patient information leaflet

Exclusion Criteria:

- Contraindications according to the patient information leaflet